| Size | Price | Stock | Qty |
|---|---|---|---|
| 10mg |
|
||
| Other Sizes |
| Targets |
Terizidone's mechanism of action involves the competitive inhibition of two key enzymes in the bacterial cell wall synthesis pathway: L-alanine racemase and D-alanine:D-alanine ligase. By inhibiting these enzymes, Terizidone impairs the formation of peptidoglycan, an essential component of the bacterial cell wall. This disruption compromises cell wall integrity, ultimately leading to bacterial cell death. This mechanism is shared with its active moiety, cycloserine, and is effective against Mycobacterium tuberculosis, including strains resistant to first-line anti-tuberculosis drugs.
|
|---|---|
| ln Vitro |
In vitro, Terizidone exhibits activity against Mycobacterium tuberculosis and other bacterial species by inhibiting cell wall synthesis. It is used in microbiological research to study bacterial resistance mechanisms. The compound's ability to disrupt peptidoglycan formation makes it a valuable tool for probing how alterations in bacterial cell wall synthesis contribute to resistance. It is considered a broad-spectrum antibiotic used as a second-line anti-tuberculosis drug, effective against both pulmonary and extrapulmonary tuberculosis.
|
| ln Vivo |
In vivo, Terizidone is administered as a second-line drug for the treatment of MDR-TB, often in conjunction with other second-line drugs. It is effective against Mycobacterium tuberculosis strains that are resistant to first-line therapies. Clinical studies have utilized Terizidone in the treatment of tuberculosis, HIV infection, and extensively drug-resistant tuberculosis. The compound is administered orally and is used internationally, though it is not approved in the United States.
|
| Enzyme Assay |
In vitro enzyme assays for Terizidone typically measure its inhibition of L-alanine racemase and D-alanine ligase. The enzymes are incubated with their respective substrates in the presence of varying concentrations of Terizidone. The activity of the enzymes is measured by quantifying the reaction products, and the IC50 is determined from dose-response curves. These assays confirm the compound's mechanism of action as an inhibitor of bacterial cell wall synthesis.
|
| Cell Assay |
In vitro cell-based assays for Terizidone are conducted using bacterial cultures, particularly Mycobacterium tuberculosis. Bacteria are treated with the compound at various concentrations, and bacterial growth is monitored. The minimum inhibitory concentration (MIC) is determined, which indicates the lowest concentration of Terizidone that inhibits visible bacterial growth. These assays confirm the compound's antibacterial activity and its efficacy against drug-resistant strains.
|
| Animal Protocol |
In vivo animal experiments for Terizidone are typically conducted in murine models of tuberculosis. Animals are infected with Mycobacterium tuberculosis and then treated with Terizidone, either alone or in combination with other drugs. The compound's efficacy is assessed by measuring bacterial load in the lungs and spleen, as well as by monitoring survival rates. These studies provide evidence for the in vivo efficacy of Terizidone in treating tuberculosis.
|
| ADME/Pharmacokinetics |
Terizidone has a molecular weight of 302.29 g/mol and a molecular formula of C14H14N4O4. It is a solid at room temperature with a melting point of 204-205 ºC and a density of 1.52. The compound is soluble in DMSO. For storage, it is recommended to keep the powder at -20°C for up to 3 years or at 4°C for up to 2 years. It should be stored in a sealed and protected environment, avoiding exposure to moisture.
|
| Toxicity/Toxicokinetics |
Terizidone is considered to have a similar safety profile to cycloserine. Common side effects may include central nervous system effects such as headache, dizziness, and confusion. As with all second-line anti-tuberculosis drugs, it should be used under medical supervision. For research use, standard laboratory safety precautions should be followed when handling Terizidone.
|
| References | |
| Additional Infomation |
Terizidone is an oxygen- and nitrogen-containing organic compound whose structure is related to α-amino acids. Terizidone has been used in clinical trials for the treatment of tuberculosis, HIV infection, multidrug-resistant tuberculosis, and extensively drug-resistant tuberculosis. Terizidone is a broad-spectrum antibiotic used as a second-line anti-tuberculosis drug, effective against both pulmonary and extrapulmonary tuberculosis. Terizidone is also active against Mycobacterium tuberculosis strains resistant to first-line anti-tuberculosis drugs.
Terizidone is a research compound and a pharmaceutical agent used for the treatment of MDR-TB. It is a prodrug of cycloserine that inhibits bacterial cell wall synthesis by targeting L-alanine racemase and D-alanine ligase. It is used internationally but is not currently approved in the United States. Terizidone has been used in clinical trials for the treatment of tuberculosis, HIV infection, and extensively drug-resistant tuberculosis. It is a valuable research tool for studying bacterial resistance mechanisms and for developing new antimicrobial strategies. |
| Molecular Formula |
C14H14N4O4
|
|---|---|
| Molecular Weight |
302.28536
|
| Exact Mass |
302.102
|
| CAS # |
25683-71-0
|
| PubChem CID |
65720
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.52
|
| Melting Point |
204-205 ºC
|
| LogP |
0.042
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
4
|
| Heavy Atom Count |
22
|
| Complexity |
441
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
O=C1NOCC1/N=C/C1C=CC(/C=N/C2CONC2=O)=CC=1
|
| InChi Key |
ODKYYBOHSVLGNU-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C14H14N4O4/c19-13-11(7-21-17-13)15-5-9-1-2-10(4-3-9)6-16-12-8-22-18-14(12)20/h1-6,11-12H,7-8H2,(H,17,19)(H,18,20)
|
| Chemical Name |
4-[[4-[(3-oxo-1,2-oxazolidin-4-yl)iminomethyl]phenyl]methylideneamino]-1,2-oxazolidin-3-one
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment (e.g. under nitrogen), avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.3081 mL | 16.5404 mL | 33.0808 mL | |
| 5 mM | 0.6616 mL | 3.3081 mL | 6.6162 mL | |
| 10 mM | 0.3308 mL | 1.6540 mL | 3.3081 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
| NCT Number | Recruitment | interventions | Conditions | Sponsor/Collaborators | Start Date | Phases |
| NCT02454205 | COMPLETED | Drug: Linezolid Drug: Bedaquiline Drug: Levofloxacin |
Extensively-drug Resistant Tuberculosis Multidrug Resistant Tuberculosis Tuberculosis |
University of Cape Town | 2015-11-12 | Phase 2 Phase 3 |
| NCT02727582 | COMPLETED | Multidrug-resistant Tuberculosis | University of Cape Town | 2015-07-30 | ||
| NCT03237182 | TERMINATED | Drug: Individualized TB treatment with multiple drugs Drug: Standardized TB treatment with multiple drugs |
Tuberculosis, Multidrug-Resistant | Centre for the AIDS Programme of Research in South Africa |
2017-06-14 | Phase 4 |
| NCT03625739 | RECRUITING | Drug: anti-tuberculosis drug | Tuberculosis | Beijing Children's Hospital | 2018-07-01 | |
| NCT00042289 | COMPLETEDWITH RESULTS | Drug: atazanavir/cobicistat Drug: darunavir/ritonavir dosage #1 Drug: darunavir/ritonavir dosage #2 |
HIV Infections | National Institute of Allergy and Infectious Diseases (NIAID) | 2003-06-09 | Observational |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
